Direxion mRNA ETF
MSGR
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- DE United States of America
- IPO Date
- Dec 9, 2021
- CIK
- 0001424958
- Similar Companies
- Business
- Direxion mRNA ETF (MSGR) is an exchange-traded fund that seeks investment results, before fees and expenses, tracking the performance of the BITA Messenger RNA Technology Index, a market-cap-weighted index comprising companies from the US, Canada, and Europe involved in the development and application of messenger RNA (mRNA) technology, including vaccines, therapeutics, and related medicines; the index attributes full thematic exposure scores to firms deriving at least 50% of revenue from mRNA or sister RNA technologies such as small interfering RNA and micro RNA. MSGR, part of the Direxion Shares ETF Trust, provides investors exposure to growth and value stocks across diversified market capitalizations in public equity markets globally, with a focus on pure-play mRNA innovators. The fund was formed on December 9, 2021, and Direxion Shares ETF Trust, domiciled in Wilmington, Delaware with principal operations in New York, serves as the issuer within Direxion's broader lineup of leveraged, inverse, and thematic ETFs managed by a firm founded in 1997. In a significant operational change, Direxion announced the closure and liquidation of MSGR, along with seven other underperforming ETFs including BRKY, TIPL, TIPD, EVEN, ONG, SWAR, and MNM, effective after the close of trading on April 21, 2023, ceasing new purchase orders and delisting the shares from NYSE Arca. This followed heightened M&A activity in the mRNA sector around the fund's 2021 launch, such as Sanofi's USD3.2 billion acquisition of Translate Bio, though no direct partnerships, funding rounds, or new product launches specific to MSGR occurred post-inception. Direxion has since expanded its portfolio with new leveraged and inverse single-stock ETFs targeting companies like Berkshire Hathaway, Palantir, Boeing, Exxon Mobil, and AMD, alongside executive appointments including Mo Sparks as Chief Product Officer in April 2025 and Douglas Yones as CEO in late 2024, while conducting reverse splits on select funds like DUST, TECS, WEBS, and YANG in early 2025. The firm maintains approximately $50.6 billion in assets under management as of June 2025, operating from offices in New York, Boston, Alexandria, and Hong Kong, targeting active traders and thematic investors in the financial services sector.